bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
232 hedge funds and large institutions have $1.71B invested in bluebird bio in 2021 Q2 according to their latest regulatory filings, with 44 funds opening new positions, 81 increasing their positions, 60 reducing their positions, and 41 closing their positions.
35% more repeat investments, than reductions
Existing positions increased: 81 | Existing positions reduced: 60
7% more capital invested
Capital invested by funds: $1.59B → $1.71B (+$118M)
1% more funds holding
Funds holding: 229 → 232 (+3)
7% more first-time investments, than exits
New positions opened: 44 | Existing positions closed: 41
0.07% more ownership
Funds ownership: 6.03% → 6.11% (+0.07%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
20% less call options, than puts
Call options by funds: $26.1M | Put options by funds: $32.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$58.8M |
| 2 |
First Trust Advisors
Wheaton,
Illinois
|
+$24.3M |
| 3 |
Goldman Sachs
New York
|
+$23.1M |
| 4 |
Point72 Asset Management
Stamford,
Connecticut
|
+$17.2M |
| 5 |
JP Morgan Chase
New York
|
+$16.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$97.2M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$30.1M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$28.2M |
| 4 |
CS
Candriam SCA
Strassen, Luxembourg,
Luxembourg
|
-$17.6M |
| 5 |
Two Sigma Investments
New York
|
-$6.9M |
BLUE Hedge Fund Activity: Q2 2021 in Review
232 of the 5,746 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q2 2021, worth a combined $1.71B — up 7.4% from $1.59B a quarter earlier.
Buyers outnumbered sellers: 44 funds opened new BLUE positions and 41 closed out — a net gain of 3 holders — while 81 added to existing stakes and 60 trimmed.
The largest buyer was BlackRock, adding an estimated $58.8M. The largest seller was Royal Bank of Canada, cutting an estimated $97.2M.
- 232 institutional investors held bluebird bio (BLUE) as of Q2 2021, up from 229 in Q1 2021.
- Funds reported $1.71B of bluebird bio stock for Q2 2021, up 7.4% quarter-over-quarter.
- 44 funds opened new bluebird bio positions in Q2 2021 and 41 closed out, a net change of +3 holders.
- The largest bluebird bio buyer in Q2 2021 was BlackRock, an estimated $58.8M added.
- The largest bluebird bio seller in Q2 2021 was Royal Bank of Canada, an estimated $97.2M sold.
Based on aggregated 13F filings for Q2 2021.